» Articles » PMID: 19053777

Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States

Overview
Journal J Med Chem
Specialty Chemistry
Date 2008 Dec 5
PMID 19053777
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Type-II kinase inhibitors represent a class of chemicals that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site. These compounds are often more specific than those that target active DFG-in kinase conformations. Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable. We present a computational protocol for converting multiple available DFG-in structures of various kinases (approximately 70% of mammalian structural kinome) into accurate and specific models of their type-II bound state. The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compound pose prediction, screening, and in silico activity profiling. Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific molecules targeting inactive kinase states.

Citing Articles

Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy.

Abdo E, Ajib I, El Mounzer J, Husseini M, Kalaoun G, Matta T Inflamm Res. 2025; 74(1):41.

PMID: 39960501 DOI: 10.1007/s00011-025-02008-5.


KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE-mediated Activation.

Wunderle V, Wilhelm T, Boukeileh S, Gossen J, Margreiter M, Sakurov R Eur J Immunol. 2024; 55(2):e202451348.

PMID: 39676406 PMC: 11830387. DOI: 10.1002/eji.202451348.


Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy.

Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P Med Drug Discov. 2024; 23.

PMID: 39281823 PMC: 11393807. DOI: 10.1016/j.medidd.2024.100195.


A Bioinformatic Analysis Predicts That Cannabidiol Could Function as a Potential Inhibitor of the MAPK Pathway in Colorectal Cancer.

du Plessis J, Deroubaix A, Omar A, Penny C Curr Issues Mol Biol. 2024; 46(8):8600-8610.

PMID: 39194723 PMC: 11352951. DOI: 10.3390/cimb46080506.


A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors.

Mehra A, Sangwan R Anticancer Agents Med Chem. 2024; 25(1):2-23.

PMID: 39192641 DOI: 10.2174/0118715206318833240819031953.


References
1.
Totrov M, Abagyan R . Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins. 1997; Suppl 1:215-20. DOI: 10.1002/(sici)1097-0134(1997)1+<215::aid-prot29>3.3.co;2-i. View

2.
Ahmad T, Eisen T . Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004; 10(18 Pt 2):6388S-92S. DOI: 10.1158/1078-0432.CCR-040028. View

3.
Akeno-Stuart N, Croyle M, Knauf J, Malaguarnera R, Vitagliano D, Santoro M . The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007; 67(14):6956-64. DOI: 10.1158/0008-5472.CAN-06-4605. View

4.
Hasegawa M, Nishigaki N, Washio Y, Kano K, Harris P, Sato H . Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem. 2007; 50(18):4453-70. DOI: 10.1021/jm0611051. View

5.
Schapira M, Totrov M, Abagyan R . Prediction of the binding energy for small molecules, peptides and proteins. J Mol Recognit. 1999; 12(3):177-90. DOI: 10.1002/(SICI)1099-1352(199905/06)12:3<177::AID-JMR451>3.0.CO;2-Z. View